As I proposed in 2011 report, cell trials tracking allows to identify some trends. Today I’d like to show you some interesting trends from 2011 to 2012.
First of all, I’d like to announce that 2011 report was updated! I’ve found a few more (6) trials, that I’ve missed, when finalized the report. My key words, by some reasons didn’t capture those trials.
Total number of trials
Total number of cell therapy trials, registered in databases increased from 2011 to 2012. I think it’s not a big jump, but good increase. This is positive and somewhat expected trend. First, the interest to the field is progressively increasing. Second, trialists were encouraged or obligated (US mandate to register trials in NCT database) to register trials in databases.
The number of cell therapy trials have increased in 2012, because the value of academic trials have increased. The number of industry-sponsored trials remained flat – from 50 in 2011 to 51 in 2012. I find this trend quite interesting.
US and China continue to dominate all other countries in number of cell therapy trials. Interestingly, the value of US and China out of top 10 countries remained flat for the last 2 years – about 31% of all trials in US and about 23% of all trials in China. From other “top 10 countries” – Iran, Spain and South Korea went up, India and Japan went down. UK didn’t make it in “top 10” and Nethderlads was a “newcomer” in 2012.
If we look at regions in general, were no big moves from 2011 to 2012. Only South America went up from 1% in 2011 to 3% in 2012.
The number of cell therapy trials increased in 2012 through the value of mesenchymal stromal cells (MSC), T-cells, bone marrow mononuclear cells (BM MNC), adipose tissue-derived MSC + stromal vascular fraction (SVF) and hematopoietic stem/ progenitor cells (HSPC). I’d especially emphasize a “big movers” – MSC and T-cells. Unlike T-cells, the other type of cellular immunotherapies – dendritic cells (DC) went down in 2012. Embryonic stem cells (ESC) remained pretty much flat (from 3 in 2011 to 2 in 2011).
The value “stem” versus “non-stem” trials did not change and remained around 50/50 from 2011 to 2012. The same trend (flat) was observed for donor type – autologous from 63% in 2011 to 60% in 2012 and allogeneic from 37% in 2011 to 34% in 2012.
Cell type demographics
This is very interesting part of analysis. It turns out that some countries “like” some particular types of cells. T-cells is absolute US favorite. Almost all trials, involved umbilical cord-derived MSC, are going on in China! Adipose tissue-derived cells is the “most popular” cell type in Spain, followed by S. Korea and Japan.
The number of trials for cancer “skyrocketed” in 2012. Neurological conditions and eye diseases are remained flat. Number of trials for cardiovascular conditions, skin diseases, muskuloskeletal diseases and diabetes went up. The number of trials for liver diseases went down.
It was a snapshot of dataset analysis for 2011 and 2012. I was trying to pick the most interesting trends. As you can see, the data could be “sliced and diced” in many different ways. Please leave your comments and discuss these trends. Please let me know, what kind of trends you would be interested in.
How to cite:
Bersenev Alexey. Cell therapy clinical trials 2012 – trends. CellTrials blog. January 15, 2013. Available: http://celltrials.info/2013/01/15/cell-trials-2012-trends/
Follow real time updates via @CellTrials
Subscribe to this blog!